2026-04-10 08:55 |
Detailed record - Similar records
|
2026-04-09 17:17 |
Detailed record - Similar records
|
2026-04-09 14:14 |
[DKFZ-2026-00814]
Journal Article
Calderón, E. ; Späth, M. S. ; Maas, M. ; et al
Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy.
We report an 81-year-old man with metastatic castration-resistant prostate cancer (mCRPC) after multiple prior therapies, including androgen deprivation therapy (ADT), the androgen receptor pathway inhibitor (ARPI) abiraterone, taxane chemotherapy with docetaxel and cabazitaxel, radiopharmaceutical therapy (RPT) with 4 cycles of [177Lu]PSMA-I&T, and the PARP inhibitor olaparib in combination with abiraterone. Due to biochemical and clinical progression, [18F]PSMA-1007 PET/CT was performed for restaging, revealing diffuse skeletal metastases without significant extraosseous disease. [...]
Detailed record - Similar records
|
2026-04-09 14:09 |
Detailed record - Similar records
|
2026-04-09 14:05 |
Detailed record - Similar records
|
2026-04-09 14:01 |
Detailed record - Similar records
|
2026-04-09 13:59 |
Detailed record - Similar records
|
2026-04-08 15:06 |
Detailed record - Similar records
|
2026-04-08 14:59 |
Detailed record - Similar records
|
2026-04-08 14:56 |
Detailed record - Similar records
|
|
|